Home > Publications Database > Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen-Treated ALS. > print

001     280914
005     20250921001947.0
024 7 _ |a 10.1002/mus.28453
|2 doi
024 7 _ |a pmid:40491248
|2 pmid
024 7 _ |a pmc:PMC12338008
|2 pmc
024 7 _ |a 0148-639X
|2 ISSN
024 7 _ |a 1097-4598
|2 ISSN
024 7 _ |a altmetric:178071998
|2 altmetric
037 _ _ |a DZNE-2025-00997
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bernsen, Sarah
|0 P:(DE-2719)9000485
|b 0
|e First author
|u dzne
245 _ _ |a Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen-Treated ALS.
260 _ _ |a New York, NY [u.a.]
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1758101153_31851
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cardiac troponin T (cTnT) levels are elevated in the majority of persons with amyotrophic lateral sclerosis (ALS) and increase over time. Neurofilament light chain (NfL) is an established therapy response biomarker in ALS as superoxide dismutase1 (SOD1)-ALS patients treated with the antisense oligonucleotide tofersen show a decrease in NfL. In this study, we assess cTnT levels in SOD1-ALS at baseline and during tofersen treatment.cTnT was analyzed at baseline and during tofersen treatment in 23 SOD1-ALS patients at two specialized ALS centers in Germany and compared to a control cohort of 74 ALS patients without SOD1 variants.cTnT levels increased in the control ALS cohort over time (p < 0.0001) but not in the tofersen group (p = 0.36). Creatine kinase (CK) and CK-MB levels did not show significant changes over time. The median monthly increase of cTnT was 0.045 points (IQR 0.02-0.08) in the control ALS cohort and 0.01 points (IQR -0.01-0.03) in the tofersen group (p = 0.0013). A significantly lower fold change in cTnT levels was observed in the tofersen-treated cohort (median 1.2; IQR 0.77-1.59) relative to the control group (median 1.89; IQR 1.35-2.75) (p = 0.0003). Nine (39%) patients treated with tofersen experienced a reduction in cTnT levels.In this study, we describe a response signal of cTnT to tofersen treatment, which supports the value of cTnT as an independent biomarker in ALS. These results contribute to the notion that cTnT may provide additional value as a progression and treatment response biomarker in ALS complementary to NfL and warrant further investigation.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a SOD1
|2 Other
650 _ 7 |a amyotrophic lateral sclerosis
|2 Other
650 _ 7 |a biomarker
|2 Other
650 _ 7 |a tofersen
|2 Other
650 _ 7 |a troponin
|2 Other
650 _ 7 |a Troponin T
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Oligonucleotides
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a Superoxide Dismutase-1
|0 EC 1.15.1.1
|2 NLM Chemicals
650 _ 7 |a Creatine Kinase
|0 EC 2.7.3.2
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: blood
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: drug therapy
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: genetics
|2 MeSH
650 _ 2 |a Troponin T: blood
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Oligonucleotides: therapeutic use
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Neurofilament Proteins
|2 MeSH
650 _ 2 |a Superoxide Dismutase-1: genetics
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Creatine Kinase: blood
|2 MeSH
700 1 _ |a Fabian, Rachel
|b 1
700 1 _ |a Koc, Yasemin
|b 2
700 1 _ |a Schumann, Peggy
|b 3
700 1 _ |a Körtvélyessy, Peter
|0 P:(DE-2719)2812030
|b 4
|u dzne
700 1 _ |a Castro-Gomez, Mario Sergio
|0 P:(DE-2719)9002230
|b 5
|u dzne
700 1 _ |a Meyer, Thomas
|0 0000-0002-2736-7350
|b 6
700 1 _ |a Weydt, Patrick
|0 P:(DE-2719)9001116
|b 7
|e Last author
|u dzne
773 _ _ |a 10.1002/mus.28453
|g Vol. 72, no. 3, p. 509 - 514
|0 PERI:(DE-600)1476641-3
|n 3
|p 509 - 514
|t Muscle & nerve
|v 72
|y 2025
|x 0148-639X
856 4 _ |u https://pub.dzne.de/record/280914/files/DZNE-2025-00997%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280914/files/DZNE-2025-00997.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/280914/files/DZNE-2025-00997.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:280914
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000485
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812030
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)9002230
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9001116
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MUSCLE NERVE : 2022
|d 2024-12-17
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-17
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-17
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-17
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-17
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 1
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a I:(DE-2719)5000006
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21